Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEASTAR: Rucaparib Combinations in Solid Tumors
NCT03992131Phase 2Terminated
- Sponsor
- pharma&
- Start
- Jun 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rucaparib in ovarian cancer, triple negative breast cancer (TNBC), urothelial carcinoma (UC), solid tumor, sponsored by pharma&. Started Jun 2019; status: terminated.
02
Drugs
rucaparib
03
Conditions
ovarian cancertriple negative breast cancer (TNBC)urothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT03992131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992131.